The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial

Article English OPEN
Carrington, Rhys ; Spezi, Emiliano ; Gwynne, Sarah ; Dutton, Peter ; Hurt, Chris ; Staffurth, John ; Crosby, Thomas (2016)
  • Publisher: BioMed Central
  • Journal: Radiation Oncology (London, England), volume 11, issue 1 (issn: 1748-717X, eissn: 1748-717X)
  • Related identifiers: doi: 10.1186/s13014-016-0594-x, pmc: PMC4744439
  • Subject: RC0254 | Radiology Nuclear Medicine and imaging | Oncology | Research

Purpose\ud \ud The first aim of this study was to assess plan quality using a conformity index (CI) and analyse its influence on patient outcome. The second aim was to identify whether clinical and technological factors including planning treatment volume (PTV) volume and treatment delivery method could be related to the CI value.\ud \ud \ud Methods and materials\ud \ud By extending the original concept of the mean distance to conformity (MDC) index, the OverMDC and UnderMDC of the 95 % isodose line (50Gy prescribed dose) to the PTV was calculated for 97 patients from the UK SCOPE 1 trial (ISCRT47718479). Data preparation was carried out in CERR, with Kaplan-Meier and multivariate analysis undertaken in EUCLID and further tests in Microsoft Excel and IBM’s SPSS.\ud \ud \ud Results\ud \ud A statistically significant breakpoint in the overall survival data, independent of cetuximab, was found with OverMDC (4.4 mm, p < 0.05). This was not the case with UnderMDC. There was a statistically significant difference in PTV volume either side of the OverMDC breakpoint (Mann Whitney p < 0.001) and in OverMDC value dependent on the treatment delivery method (mean IMRT = 2.1 mm, mean 3D-CRT = 4.1 mm Mann Whitney p < 0.001). Re-planning the worst performing patients according to OverMDC from 3D-CRT to VMAT resulted in a mean reduction in OverMDC of 2.8 mm (1.6–4.0 mm). OverMDC was not significant in multivariate analysis that included age, sex, staging, tumour type, and position.\ud \ud \ud Conclusion\ud \ud Although not significant when included in multivariate analysis, we have shown in univariate analysis that a patient’s OverMDC is correlated with overall survival. OverMDC is strongly related to IMRT and to a lesser extent with PTV volume. We recommend that VMAT planning should be used for oesophageal planning when available and that attention should be paid to the conformity of the 95 % to the PTV.
  • References (30)
    30 references, page 1 of 3

    1. Bohsung J, Gillis S, Arrans R, Bakai A, De Wagter C, Knöös T, et al. IMRT treatment planning-A comparative inter-system and inter-centre planning exercise of the ESTRO QUASIMODO group. Radiother Oncol. 2005;76(3):354-61.

    2. Teoh AYB, Chiu PWY, Yeung WK, Liu SYW, Wong SKH, Ng EKW. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol. 2013;24(1):165-71.

    3. Wolf MC, Stahl M, Krause BJ, Bonavina L, Bruns C, Belka C, et al. Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol. 2011;6:55.

    4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.

    5. Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer - A meta-analysis of the randomized trials. Cancer Treat Rev. 2012;38(6):599-604.

    6. International Commission on Radiation Units and Measurements (ICRU). Prescribing, Recording and Reporting Photon Beam Therapy. ICRU Report 50. Bethesda: ICRU; 1993.

    7. International Commission on Radiation Units and Measurements (ICRU). Prescribing, Recording and Reporting Photon Beam Therapy [supplement to ICRU Report 50]. ICRU Report 62. Bethesda: ICRU; 1999.

    8. Warren S, Partridge M, Carrington R, Hurt C, Crosby T, Hawkins M. Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2014;90:423-9.

    9. Vidal M, Vieillevigne L, Izar F, Ferrand R. Dosimetric comparison of RapidArc and 3D-Conformal RT for esophageal cancer. Physica Medica. 2012;28(Supplement 1):S2-3.

    10. Weber DC, Tomsej M, Melidis C, Hurkmans CW. QA makes a clinical trial stronger: Evidence-based medicine in radiation therapy. Radiother Oncol. 2012;105:4-8.

  • Metrics
    No metrics available
Share - Bookmark